UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

The FTSE 100 and European stocks were mixed at the open on Monday, as traders digest the potential of escalating tensions ...

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock ...

The FTSE 100 and European stocks were mixed at the open on Monday, as traders digest the potential of escalating tensions between European powers, Ukraine and Russia. London's pre ...

Shares in TSMC (TSM, 2330.TW) rose more than 2% on Monday, after it was reported that the chipmaker was considering taking a ...

After years of limping along, the GSK share price has leapt 11% in one month. But one of America's richest investors is ...

The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s stock for more than a decade, The Times’ Ben Martin ...

Moderna's norovirus vaccine trial paused due to a rare neurological effect, Citadel's short position in GSK, bird flu response issues during Trump's term, WHO's call for alcohol warning labels, and ...

(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...

Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...